TransEnterix, Inc. (NYSE:TRXC) is now up 24.27% compared to a 12-month low of $1.03. We have seen the price to move 2.4% higher and get settled at $1.28 on 6/27/2019. At recent session, it appeared stuck in a range of $1.19 to $1.27. This company shares are 116.41% off its target price of $2.77 and the current market capitalization stands at $289.16M. The recent change has given its price a -18.2% deficit over SMA 50 and -81.66% deficit over its 52-week high. The stock witnessed -6.57% declines, -42.86% declines and -47.76% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TRXC’s volatility during a week at 6.33% and during a month it has been found around 6.66%.

What Does TransEnterix, Inc. (TRXC) Do?

The company describes itself in regulatory filings as, “TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.” [Text can be found here: under company description.]

TransEnterix, Inc. (TRXC) Top Holders

Institutional investors currently hold around $95 million or 36.4% in TRXC stock. Look at its top three institutional owners: Blackrock Inc. owns $16.61 million in TransEnterix, Inc., which represents roughly 5.74% of the company’s market cap and approximately 17.48% of the institutional ownership. Similar statistics are true for the second largest owner, Jpmorgan Chase & Co, which owns 8,285,135 shares of the stock are valued at $10.36 million. The third largest holder is Vanguard Group Inc, which currently holds $10.3 million worth of this stock and that ownership represents nearly 3.56% of its market capitalization.

TransEnterix, Inc. 13F Filings

At the end of March reporting period, 77 institutional holders increased their position in TransEnterix, Inc. (NYSE:TRXC) by some 7,942,868 shares, 49 decreased positions by 4,735,168 and 49 held positions by 63,081,927. That puts total institutional holdings at 75,759,963 shares, according to SEC filings. The stock grabbed 23 new institutional investments totaling 3,736,153 shares while 22 institutional investors sold out their entire positions totaling 1,115,174 shares.

TransEnterix, Inc. (NYSE:TRXC) Insider Trades

Multiple company employees have indulged in significant insider trading. TransEnterix, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP and CFO SLATTERY JOSEPH P has sold 88,871 shares of TransEnterix, Inc. (TRXC) in the trading session dated Feb. 22, 2019. These shares are worth $288,831 and were traded at $3.25 each. The SEC filing shows that SLATTERY JOSEPH P performed a sale of 64,651 shares. The EVP and CFO disposed these shares by way of transaction on Oct. 02, 2018. The company’s shares were given away at $5.74 per share worth to an income of some $371,097 to the account of SLATTERY JOSEPH P.

Director, Starling William N JR, sold 3,614,649 common shares of TransEnterix, Inc. (TRXC) in the open market. In a transaction dated Sep. 27, 2018, the shares were put up for sale at an average price of $6.28, raking in a sum of $22,699,996. After this sale, 2,220,460 common shares of TRXC are directly owned by the insider, with total stake valued at $2,842,189.

In the transaction dated Sep. 25, 2018, a great number of shares sold came courtesy the EVP and CFO; SLATTERY JOSEPH P disposed a total of 4,924 shares at an average price of $7.03, amounting to approximately $34,616. The insider now directly owns 25,000 shares worth $32,000.

TransEnterix, Inc. (TRXC) Analyst Guide

Several analysts have released their opinion on TransEnterix, Inc. (NYSE:TRXC), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation [T1].